1. Home
  2. DENN vs SLN Comparison

DENN vs SLN Comparison

Compare DENN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DENN
  • SLN
  • Stock Information
  • Founded
  • DENN 1953
  • SLN 1994
  • Country
  • DENN United States
  • SLN United Kingdom
  • Employees
  • DENN N/A
  • SLN N/A
  • Industry
  • DENN Restaurants
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DENN Consumer Discretionary
  • SLN Health Care
  • Exchange
  • DENN Nasdaq
  • SLN Nasdaq
  • Market Cap
  • DENN 211.7M
  • SLN 227.2M
  • IPO Year
  • DENN 1989
  • SLN N/A
  • Fundamental
  • Price
  • DENN $4.81
  • SLN $5.23
  • Analyst Decision
  • DENN Strong Buy
  • SLN Buy
  • Analyst Count
  • DENN 7
  • SLN 5
  • Target Price
  • DENN $6.96
  • SLN $32.60
  • AVG Volume (30 Days)
  • DENN 636.3K
  • SLN 56.8K
  • Earning Date
  • DENN 10-21-2025
  • SLN 08-07-2025
  • Dividend Yield
  • DENN N/A
  • SLN N/A
  • EPS Growth
  • DENN N/A
  • SLN N/A
  • EPS
  • DENN 0.30
  • SLN N/A
  • Revenue
  • DENN $455,727,000.00
  • SLN $27,169,000.00
  • Revenue This Year
  • DENN $7.57
  • SLN N/A
  • Revenue Next Year
  • DENN $1.89
  • SLN N/A
  • P/E Ratio
  • DENN $15.85
  • SLN N/A
  • Revenue Growth
  • DENN 0.06
  • SLN 22.28
  • 52 Week Low
  • DENN $2.85
  • SLN $1.97
  • 52 Week High
  • DENN $7.73
  • SLN $20.48
  • Technical
  • Relative Strength Index (RSI)
  • DENN 67.51
  • SLN 46.66
  • Support Level
  • DENN $4.31
  • SLN $4.77
  • Resistance Level
  • DENN $4.61
  • SLN $5.29
  • Average True Range (ATR)
  • DENN 0.21
  • SLN 0.40
  • MACD
  • DENN 0.05
  • SLN -0.02
  • Stochastic Oscillator
  • DENN 98.89
  • SLN 38.82

About DENN Denny's Corporation

Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: